Trial Profile
Risperidone and atomoxetine in the treatment of severe and challenging behaviours in children with pervasive developmental disorders
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2015
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary) ; Risperidone (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- 27 Oct 2015 New trial record
- 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.